News

MVP Data Reveals Gene Mutations Ruling Cholesterol

VA researchers have identified 3 genetic mutations that govern cholesterol levels, which could lead to new drugs to treat cardiovascular disease and diabetes mellitus (DM).


 

Using data from the Million Veteran Program (MVP), researchers found people with mutations for PDE3B, PCSK9, and ANGPTL4 had better cholesterol and triglyceride levels than did those without the mutations.

The PDE3B mutation seems to protect against heart disease. A PCSK9 mutation may reduce the risk not only of heart disease, but also abdominal aortic aneurysm. The ANGPTL4 mutation was linked to lower risk of type 2 DM.

MVP, 1 of the world’s largest databases of health and genomic information, partners with veterans receiving care in the VHA to study how genes affect health. It has enrolled > 700,000 veterans to date.

Recommended Reading

Bolus Insulin Prescribing Recommendations for Patients With Type 2 Diabetes Mellitus (FULL)
Federal Practitioner
Serious Mental Illness and Its Impact on Diabetes Care in a VA Nurse/Pharmacist-Managed Population (FULL)
Federal Practitioner
Evaluating Management and Change in Glycemic Control After Discontinuation of Metformin in Patients With Elevated Serum Creatinine (FULL)
Federal Practitioner
Concentrated Insulins: A Review and Recommendations (FULL)
Federal Practitioner
Diabetes Programs Aren’t Reaching Their Targets
Federal Practitioner
Smart insoles reduce ‘high-risk’ diabetic foot ulcer recurrence
Federal Practitioner
DPP-4 drugs for diabetes may protect kidneys too
Federal Practitioner
Gastric Banding vs Metformin
Federal Practitioner
Gene Mutation May Lower Cardiometabolic Risk
Federal Practitioner
Cardiologist: Obesity has basically stopped progress on cardiovascular disease
Federal Practitioner